Customer Service: 866-788-9007
×
Cutaneous Melanoma
DecisionDXSketchesV11_DecisionDXCMSeqColor.eps

DecisionDx®-CMSeq Overview

Next-generation Sequencing for Cutaneous Melanoma

Our DecisionDx-CMSeq is a 3-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to cutaneous melanoma in melanoma tumor tissue.  The test includes hotspot mutations in the genes BRAF, NRAS and KIT.

Informed Therapy Choices Based on Identification of Somatic Mutations

Mutations in these genes are important to help inform therapy choices for melanoma patients in the adjuvant and metastatic settings, including clinical trial opportunities. There are FDA-approved therapies that target the BRAF mutation and downstream pathways in metastatic melanoma. The FDA has also approved adjuvant targeted combination therapy for resected Stage III melanoma based on recent evidence. Ongoing clinical trials evaluating new targeted therapies may also enroll patients based on the mutation status of these genes.

Ability to Obtain Both Prognostic and Therapeutic Tumor Profiles

The DecisionDx-CMSeq test can be ordered on formalin-fixed paraffin embedded (FFPE) primary tumor tissue either:

  • In conjunction with the DecisionDx®-Melanoma gene expression profile (GEP) test to obtain both a prognostic and therapeutic profile of the tumor at the same time
  • Or the DecisionDx-CMSeq test can also be ordered separately on FFPE tissue from the primary tumor, lymph node or metastasis

It is important to remember that information from the DecisionDx-CMSeq gene sequencing panel is NOT a substitute for the DecisionDx-Melanoma GEP test.

“The DecisionDx-CMSeq test can be ordered at the same time as the DecisionDx®-Melanoma test, which provides treatment information for patients at high risk.”

Surgical Oncologist

Scroll to Top